These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16001167)

  • 1. Camptothecin analogs with enhanced activity against human breast cancer cells. II. Impact of the tumor pH gradient.
    Adams DJ; Wahl ML; Flowers JL; Sen B; Colvin M; Dewhirst MW; Manikumar G; Wani MC
    Cancer Chemother Pharmacol; 2006 Jan; 57(2):145-54. PubMed ID: 16001167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Camptothecin analogues with enhanced antitumor activity at acidic pH.
    Adams DJ; Dewhirst MW; Flowers JL; Gamcsik MP; Colvin OM; Manikumar G; Wani MC; Wall ME
    Cancer Chemother Pharmacol; 2000; 46(4):263-71. PubMed ID: 11052623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Camptothecin analogs with enhanced activity against human breast cancer cells. I. Correlation of potency with lipophilicity and persistence in the cleavage complex.
    Adams DJ; da Silva MW; Flowers JL; Kohlhagen G; Pommier Y; Colvin OM; Manikumar G; Wani MC
    Cancer Chemother Pharmacol; 2006 Jan; 57(2):135-44. PubMed ID: 16151810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The activity of camptothecin analogues is enhanced in histocultures of human tumors and human tumor xenografts by modulation of extracellular pH.
    Flowers JL; Hoffman RM; Driscoll TA; Wall ME; Wani MC; Manikumar G; Friedman HS; Dewhirst M; Colvin OM; Adams DJ
    Cancer Chemother Pharmacol; 2003 Sep; 52(3):253-61. PubMed ID: 12783198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of p21WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer drugs 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways.
    Liu W; Zhang R
    Int J Oncol; 1998 Apr; 12(4):793-804. PubMed ID: 9499438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity to camptothecin of human breast carcinoma and normal endothelial cells.
    Jones CB; Clements MK; Wasi S; Daoud SS
    Cancer Chemother Pharmacol; 1997; 40(6):475-83. PubMed ID: 9332461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel-induced apoptosis is blocked by camptothecin in human breast and pancreatic cancer cells.
    Jeansonne DP; Koh GY; Zhang F; Kirk-Ballard H; Wolff L; Liu D; Eilertsen K; Liu Z
    Oncol Rep; 2011 May; 25(5):1473-80. PubMed ID: 21331447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.
    Minko T; Paranjpe PV; Qiu B; Lalloo A; Won R; Stein S; Sinko PJ
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):143-50. PubMed ID: 12172980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells.
    Gupta M; Fan S; Zhan Q; Kohn KW; O'Connor PM; Pommier Y
    Clin Cancer Res; 1997 Sep; 3(9):1653-60. PubMed ID: 9815856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 Tat peptide immunoconjugates differentially sensitize breast cancer cells to selected antiproliferative agents that induce the cyclin-dependent kinase inhibitor p21WAF-1/CIP-1.
    Hu M; Wang J; Chen P; Reilly RM
    Bioconjug Chem; 2006; 17(5):1280-7. PubMed ID: 16984139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair.
    Fujimori A; Gupta M; Hoki Y; Pommier Y
    Mol Pharmacol; 1996 Dec; 50(6):1472-8. PubMed ID: 8967967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Camptothecin analogs in malignant gliomas: comparative analysis and characterization.
    Sampath P; Amundson E; Wall ME; Tyler BM; Wani MC; Alderson LM; Colvin M; Brem H; Weingart JD
    J Neurosurg; 2003 Mar; 98(3):570-7. PubMed ID: 12650430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic antitumor activity of troxacitabine and camptothecin in selected human cancer cell lines.
    Kim TE; Park SY; Hsu CH; Dutschman GE; Cheng YC
    Mol Pharmacol; 2004 Aug; 66(2):285-92. PubMed ID: 15266019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of poly(ethylene glycol)-camptothecin conjugate: the inhibition of tumor growth in vivo.
    Yu D; Peng P; Dharap SS; Wang Y; Mehlig M; Chandna P; Zhao H; Filpula D; Yang K; Borowski V; Borchard G; Zhang Z; Minko T
    J Control Release; 2005 Dec; 110(1):90-102. PubMed ID: 16271793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complex response of breast epithelial cell lines to topoisomerase inhibitors.
    Davis PL; Shaiu WL; Scott GL; Iglehart JD; Hsieh TS; Marks JR
    Anticancer Res; 1998; 18(4C):2919-32. PubMed ID: 9713486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations.
    Yang CJ; Horton JK; Cowan KH; Schneider E
    Cancer Res; 1995 Sep; 55(18):4004-9. PubMed ID: 7664272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH.
    Gabr A; Kuin A; Aalders M; El-Gawly H; Smets LA
    Cancer Res; 1997 Nov; 57(21):4811-6. PubMed ID: 9354443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of clusterin, XIAP and survivin, and their changes by camptothecin (CPT) treatment in CPT-resistant PC-3 and CPT-sensitive LNCaP cells.
    Mizutani K; Matsumoto K; Hasegawa N; Deguchi T; Nozawa Y
    Exp Oncol; 2006 Sep; 28(3):209-15. PubMed ID: 17080014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nitric Oxide Down-Regulates Topoisomerase I and Induces Camptothecin Resistance in Human Breast MCF-7 Tumor Cells.
    Sharma NK; Kumar A; Kumari A; Tokar EJ; Waalkes MP; Bortner CD; Williams J; Ehrenshaft M; Mason RP; Sinha BK
    PLoS One; 2015; 10(11):e0141897. PubMed ID: 26540186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin.
    Kapoor R; Slade DL; Fujimori A; Pommier Y; Harker WG
    Oncol Res; 1995; 7(2):83-95. PubMed ID: 7579731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.